CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid

Toxicology and Applied Pharmacology

Volumn 266, Issue 2, 2013, Pages 245-253

  Cheng, Jie ^a   Krausz, Kristopher W ^a   Li, Feng ^b   Ma, Xiaochao ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2E1; Drug induced hepatotoxicity; Isoniazid; Metabolomics

Indexed keywords

BILE ACID; CARNITINE; CARNITINE DERIVATIVE; CHOLESTEROL; CYTOCHROME P450 2E1; FATTY ACID; ISONIAZID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG METABOLISM; FATTY ACID OXIDATION; IN VIVO STUDY; LIVER TOXICITY; MALE; METABOLOMICS; MITOCHONDRION; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTITUBERCULAR AGENTS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CARNITINE; CHOLESTEROL; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; FATTY ACIDS, NONESTERIFIED; ISONIAZID; LIVER; MALE; METABOLOMICS; MICE; MICE, KNOCKOUT; TRIGLYCERIDES;

MUS;

EID: 84871835693     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.10.024     Document Type: Article

References (30)

1. An H.R., Wu X.Q., Wang Z.Y., Zhang J.X., Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin. Exp. Pharmacol. Physiol. 2012, 39:535-543.
2. Black M., Mitchell J.R., Zimmerman H.J., Ishak K.G., Epler G.R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
3. Centers for Disease, C., and Prevention Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR Morb. Mortal. Wkly Rep. 2010, 59:224-229.
4. Chen W., Guo J.X., Chang P. The effect of taurine on cholesterol metabolism. Mol. Nutr. Food Res. 2012, 56:681-690.
5. Cheng J., Ma X., Krausz K.W., Idle J.R., Gonzalez F.J. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 2009, 37:1611-1621.
6. Cho J.Y., Kang D.W., Ma X., Ahn S.H., Krausz K.W., Luecke H., Idle J.R., Gonzalez F.J. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 2009, 50:924-937.
7. Denk G.U., Kleiss C.P., Wimmer R., Vennegeerts T., Reiter F.P., Schulz S., Zischka H., Rust C. Tauro-beta-muricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential. Biochem. Biophys. Res. Commun. 2012, 424:758-764.
8. Ghanayem B.I., Hoffler U. Investigation of xenobiotics metabolism, genotoxicity, and carcinogenicity using Cyp2e1(-/-) mice. Curr. Drug Metab. 2007, 8:728-749.
9. Gonzalez F.J. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab. Dispos. 2007, 35:1-8.
10. Hofmann A.F. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 2004, 36:703-722.
11. Hussain Z., Kar P., Husain S.A. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J. Exp. Biol. 2003, 41:1226-1232.
12. Kubitz, R., Droge, C., Stindt, J., Weissenberger, K., Haussinger, D., in press. The bile salt export pump (BSEP) in health and disease. Clin. Res. Hepatol. Gastroenterol.
13. Lee S.S., Buters J.T., Pineau T., Fernandez-Salguero P., Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 1996, 271:12063-12067.
14. Li F., Miao Y., Zhang L., Neuenswander S.A., Douglas J.T., Ma X. Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine. Drug Metab. Pharmacokinet. 2011, 26:569-576.
15. Liu Y., Qiu de K., Ma X. Liver X receptors bridge hepatic lipid metabolism and inflammation. J. Dig. Dis. 2012, 13:69-74.
16. McCarty M.F., Gustin J.C. Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids. Med. Hypotheses 1999, 52:407-416.
17. Mitchell J.J., Trakadis Y.J., Scriver C.R. Phenylalanine hydroxylase deficiency. Genet. Med. 2011, 13:697-707.
18. Perez M.J., Macias R.I., Duran C., Monte M.J., Gonzalez-Buitrago J.M., Marin J.J. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J. Hepatol. 2005, 43:324-332.
19. Possuelo L.G., Castelan J.A., de Brito T.C., Ribeiro A.W., Cafrune P.I., Picon P.D., Santos A.R., Teixeira R.L., Gregianini T.S., Hutz M.H., Rossetti M.L., Zaha A. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 2008, 64:673-681.
20. Reuter, S.E., Evans, A.M., in press. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin. Pharmacokinet.
21. Schulte E.K. Standardization of biological dyes and stains: pitfalls and possibilities. Histochemistry 1991, 95:319-328.
22. Shen C., Meng Q., Zhang G., Hu W. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br. J. Pharmacol. 2008, 153:784-791.
23. Sotsuka T., Sasaki Y., Hirai S., Yamagishi F., Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In vivo 2011, 25:803-812.
24. Stefanovic-Racic M., Perdomo G., Mantell B.S., Sipula I.J., Brown N.F., O'Doherty R.M. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E969-E977.
25. Teixeira R.L., Morato R.G., Cabello P.H., Muniz L.M., Moreira Ada S., Kritski A.L., Mello F.C., Suffys P.N., Miranda A.B., Santos A.R. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem. Inst. Oswaldo Cruz 2011, 106:716-724.
26. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 2010, 28:220-224.
27. Woo J., Chan C.H., Walubo A., Chan K.K. Hydrazine-a possible cause of isoniazid-induced hepatic necrosis. J. Med. 1992, 23:51-59.
28. Yue J., Peng R. Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?. Br. J. Pharmacol. 2009, 157:331-333.
29. Yue J., Peng R.X., Yang J., Kong R., Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol. Sin. 2004, 25:699-704.
30. Yue J., Peng R., Chen J., Liu Y., Dong G. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacol. Res. 2009, 59:112-119.